Sage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again

Dow Jones

Nov 20, 2024

By Colin Kellaher

Sage Therapeutics shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure.

Sage shares, which closed Tuesday at $4.91, were recently down 26% to $3.62 in premarket trading.

The company on Wednesday said a Phase 2 study of dalzanemdor missed its goals in patients with cognitive impairment associated with the brain disorder Huntington's disease.

Based on these results, the company does not plan further development of dalzanemdor.

Sage earlier this year reported similar Phase 2 study failures of dalzanemdor in Alzheimer's and Parkinson's diseases, and the Cambridge, Mass., company last month slashed a third of its workforce.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

November 20, 2024 06:59 ET (11:59 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2484103192"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2484103192\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2484103192?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-20 19:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484103192","market":"sg","top_or_hot":-1,"title":"Sage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure. \n</p>\n<p>\n  Sage shares, which closed Tuesday at $4.91, were recently down 26% to $3.62 in premarket trading. \n</p>\n<p>\n  The company on Wednesday said a Phase 2 study of dalzanemdor missed its goals in patients with cognitive impairment associated with the brain disorder Huntington's disease. \n</p>\n<p>\n  Based on these results, the company does not plan further development of dalzanemdor. \n</p>\n<p>\n  Sage earlier this year reported similar Phase 2 study failures of dalzanemdor in Alzheimer's and Parkinson's diseases, and the Cambridge, Mass., company last month slashed a third of its workforce. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 20, 2024 06:59 ET (11:59 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSage Therapeutics Shares Slide Premarket After Dalzanemdor Fails Again\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-20 19:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SAGE\">Sage Therapeutics</a> shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure. \n</p>\n<p>\n  Sage shares, which closed Tuesday at $4.91, were recently down 26% to $3.62 in premarket trading. \n</p>\n<p>\n  The company on Wednesday said a Phase 2 study of dalzanemdor missed its goals in patients with cognitive impairment associated with the brain disorder Huntington's disease. \n</p>\n<p>\n  Based on these results, the company does not plan further development of dalzanemdor. \n</p>\n<p>\n  Sage earlier this year reported similar Phase 2 study failures of dalzanemdor in Alzheimer's and Parkinson's diseases, and the Cambridge, Mass., company last month slashed a third of its workforce. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 20, 2024 06:59 ET (11:59 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2484103192","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484103192","pubTimestamp":1732103940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sage Therapeutics shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure.Sage shares, which closed Tuesday at $4.91, were recently down 26% to $3.62 in premarket trading.The company on Wednesday said a Phase 2 study of dalzanemdor missed its goals in patients with cognitive impairment associated with the brain disorder Huntington's disease.Based on these results, the company does not plan further development of dalzanemdor.Sage earlier this year reported similar Phase 2 study failures of dalzanemdor in Alzheimer's and Parkinson's diseases, and the Cambridge, Mass., company last month slashed a third of its workforce.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SAGE":"Sage Therapeutics"},"translate_title":"Dalzanemdor再次失败后，Sage Therapeutics股价盘前下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SAGE":1},"content_text":"By Colin Kellaher \n\n\n \n\n\nSage Therapeutics shares tumbled in premarket trading Wednesday after the biopharmaceutical company threw in the towel on dalzanemdor following the drug candidate's latest study failure. \n\n\n  Sage shares, which closed Tuesday at $4.91, were recently down 26% to $3.62 in premarket trading. \n\n\n  The company on Wednesday said a Phase 2 study of dalzanemdor missed its goals in patients with cognitive impairment associated with the brain disorder Huntington's disease. \n\n\n  Based on these results, the company does not plan further development of dalzanemdor. \n\n\n  Sage earlier this year reported similar Phase 2 study failures of dalzanemdor in Alzheimer's and Parkinson's diseases, and the Cambridge, Mass., company last month slashed a third of its workforce. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2024 06:59 ET (11:59 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}